IO Research Pays Off in MSI-H/dMMR CRC but Misses the Mark in MSS/pMMR Disease
Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.
Related Articles
Subcutaneous Amivantamab Wins EU Approval in Multiple EGFR+ Advanced NSCLC Indications
The European Commission has approved subcutaneous amivantamab in multiple indications in advanced EGFR-mutant non–small cell lung cancer.
Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer
IHC staining is top of mind for the use of ADCs in cervical cancer management; however, the specific indications for each agent must be considered.
Second-Line Sequencing May Hinge on IHC Staining in Cervical Cancer
IHC staining is top of mind for the use of ADCs in cervical cancer management; however, the specific indications for each agent must be considered.
IO Research Pays Off in MSI-H/dMMR CRC but Misses the Mark in MSS/pMMR Disease
Tanios S. Bekaii-Saab, MD, discusses questions that have arisen regarding the use of immunotherapy in patients with MSI-H/dMMR and MSS/pMMR CRC.
Talazoparib Plus Enzalutamide Improves rPFS Regardless of AR Alteration Status in mCRPC
Talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide in patients with mCRPC with or without AR alterations.
AACR Annual Meeting
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Olaparib Plus Pembrolizumab Shows Efficacy in HRR Gene–Mutated Advanced Tumors With/Without HRD Positivity
Olaparib plus pembrolizumab was safe and effective in HRR gene–mutated and/or HRD-positive advanced tumors.
AACR Annual Meeting
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
First-Line Penpulimab Plus Chemo Extends PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma
Penpulimab plus chemotherapy improved progression-free survival in recurrent or metastatic nasopharyngeal carcinoma.
TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC
Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.